I'm delighted to introduce the journal of pharmacogenomics and pharmacoproteomics publishes articles on fresh developments in the field of tailored drugs. The original research articles or contemporary reviews that are published in the journal deal with the impact of genetic variants on patient drug response and vice versa. The journal intends to report new developments in proteome-based personalised medication discovery. The magazine offers a forum with open access for the publication of recent developments in medication delivery, development, and design. I'm happy to report that, during the year 2019, every issue of volume 10 was published online on time and in print, with delivery occurring within 30 days of online publication. The journal aims to publish the most comprehensive and trustworthy source of information on the cutting-edge and most recent research topics related to recent advancements in quantitative proteomics, translational research, biomarker identification, metabolomics, biomolecular & analytical mass spectrometry, bioinformatics tools, and bioinformatics databases. Genome research centers around the world are working on the Human Genome Project (HGP) with the ultimate goal of elucidating and characterizing the complete sequence of 3 at 109 base pairs (bp) located in approximately 85,000 genes in the human genome. I'm out. An even bigger task is to determine their function and interaction. The genome project's genomic approach to mapping and sequencing has accelerated the rate of gene discovery. In 1990, 1772 human genes were identified and assigned to specific chromosomes or regions of the genome. In September 1996, the number was 3,868 genes, more than doubled. As of June 1996, 62 human genes associated with human disease had been isolated by genomic technology, 51 (82%) of which were publicly available as clones or DNA sequences. In addition, biomedical research is rapidly defining the molecular mechanisms of pharmacological effects, the genetic determinants of disease etiology, and the functionally important polymorphisms of genes that control drug metabolism and pharmacokinetics. A radically new but complementary approach to drug development is now emerging, promising dramatic improvements in the efficiency and speed of drug development. This approach leverages new technical expertise from pharmacological genetics, pharmacogenomics, and functional genomics to analyze, predict, and monitor the nature of an individual's response to a drug. Ultimately, this can lead to smaller and more rapid clinical trials, which can lead to individually tailored pharmacological treatments. This approach can have fundamental consequences for disease planning, clinical trials, and treatment. An important achievement of molecular medicine is the development of technology to introduce therapeutic genes into cultured cells and in vivo tissues, which has the potential to be applied to both medical research and clinical medical practice. If we can use the genome database to search for new drug discovery targets and rapidly accumulate human gene sequences to convert molecular levels into improved interventions, we have great promise in clinical medicine. Whenever possible, a therapeutic agent can be designed with a specific molecular function, whether it is a gene product that is deficient or aberrant in the patient, or a drug that has a direct transcription or molecular effect.